Vismodegib for periocular and orbital basal cell carcinoma

JAMA Ophthalmology

Volumn 131, Issue 12, 2013, Pages 1591-1594

  Gill, Harmeet S ^a   Moscato, Eve E ^b   Chang, Anne Lynn S ^c   Soon, Seaver ^d   Silkiss, Rona Z ^b  

^a UNIVERSITY OF TORONTO   (Canada)

^b CALIFORNIA PACIFIC MEDICAL CENTER   (United States)

^c STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d SCRIPPS CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

VISMODEGIB;

ADULT; AGED; ALOPECIA; ANOREXIA; BASAL CELL CARCINOMA; CANCER INFILTRATION; CLINICAL ARTICLE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DYSGEUSIA; FEASIBILITY STUDY; FEMALE; FOLLOW UP; HUMAN; MALE; MIDDLE AGED; MUSCLE CRAMP; OBSERVATIONAL STUDY; ORBIT CANCER; ORBITAL BASAL CELL CARCINOMA; PERIOCULAR BASAL CELL CARCINOMA; PRIORITY JOURNAL; REVIEW; SQUAMOUS CELL CARCINOMA; TREATMENT DURATION; TREATMENT RESPONSE; TUMOR GROWTH; TUMOR RECURRENCE; TUMOR VOLUME; VERY ELDERLY;

ADMINISTRATION, ORAL; ADULT; AGED; AGED, 80 AND OVER; ANILIDES; ANTINEOPLASTIC AGENTS; CARCINOMA, BASAL CELL; EYELID NEOPLASMS; FEMALE; FOLLOW-UP STUDIES; HEDGEHOG PROTEINS; HUMANS; MALE; MIDDLE AGED; ORBITAL NEOPLASMS; PILOT PROJECTS; PROSPECTIVE STUDIES; PYRIDINES; SKIN NEOPLASMS; TREATMENT OUTCOME;

EID: 84891592058     PISSN: 21686165     EISSN: None     Source Type: Journal    
DOI: 10.1001/jamaophthalmol.2013.5018     Document Type: Review

References (17)

1. Cook BE Jr, Bartley GB. Epidemiologic characteristics and clinical course of patients with malignant eyelid tumors in an incidence cohort in Olmsted County, Minnesota. Ophthalmology. 1999;106 (4):746-750.
2. Ceilley RI, Del Rosso JQ. Current modalities and new advances in the treatment of basal cell carcinoma. Int J Dermatol. 2006;45 (5):489-498.
3. Cook BE Jr, Bartley GB. Treatment options and future prospects for the management of eyelid malignancies. Ophthalmology. 2001;108 (11):2088-2098; quiz 2099-2100; 2121.
4. Mohs FE.Micrographic surgery for the microscopically controlled excision of eyelid cancers. Arch Ophthalmol. 1986;104 (6):901-909.
5. Glatt HJ, Olson JJ, Putterman AM. Conventional frozen sections in periocular basal-cell carcinoma. Ophthalmic Surg. 1992;23 (1):6-8; discussion 9.
6. Kakudo N, Ogawa Y, Suzuki K, Kushida S, Kusumoto K. Clinical outcome of surgical treatment for periorbital basal cell carcinoma. Ann Plast Surg. 2009;63 (5):531-535.
7. Wong VA, Marshall JA, Whitehead KJ,Williamson RM, Sullivan TJ. Management of periocular basal cell carcinoma with modified en face frozen section controlled excision. Ophthal Plast Reconstr Surg. 2002;18 (6):430-435.
8. Sekulic A, Migden MR, Oro AE, et al. Efficacy and safety of vismodegib in advanced basal-cell carcinoma. N Engl J Med. 2012;366 (23):2171-2179.
9. Harris LG, Samant RS, Shevde LA. Hedgehog signaling. Mol Cancer Res. 2011;9 (9):1165-1174.
10. Aszterbaum M, Rothman A, Johnson RL, et al. Identification of mutations in the human PATCHED gene in sporadic basal cell carcinomas and in patients with the basal cell nevus syndrome. J Invest Dermatol. 1998;110 (6):885-888.
11. Taipale J, Chen JK, Cooper MK, et al. Effects of oncogenic mutations in smoothened and patched can be reversed by cyclopamine. Nature. 2000;406 (6799):1005-1009.
12. Graham RA, Lum BL, Cheeti S, et al. Pharmacokinetics of hedgehog pathway inhibitor vismodegib (GDC-0449) in patients with locally advanced or metastatic solid tumors. Clin Cancer Res. 2011;17 (8):2512-2520.
13. Aasi S, Silkiss R, Tang JY, et al. New onset of keratoacanthomas after vismodegib treatment for locally advanced basal cell carcinomas: a report of 2 cases. JAMA Dermatol. 2013;149 (2):242-243.
14. Arnault JP, Mateus C, Escudier B, et al. Skin tumors induced by sorafenib. Clin Cancer Res. 2012;18 (1):263-272.
15. Von Hoff DD, LoRusso PM, Rudin CM, et al. Inhibition of the hedgehog pathway in advanced basal-cell carcinoma. N Engl J Med. 2009;361 (12):1164-1172.
16. Tang JY, Mackay-Wiggan JM, Aszterbaum M, et al. Inhibiting the hedgehog pathway in patients with the basal-cell nevus syndrome. N Engl J Med. 2012;366 (23):2180-2188.
17. Yauch RL, Dijkgraaf GJ, Alicke B, et al. Smoothened mutation confers resistance to a Hedgehog pathway inhibitor in medulloblastoma. Science. 2009;326 (5952):572-574.